Immuno-PRISM (PRecision Intervention Smoldering Myeloma): A Randomized Phase II Platform Study of Select Immunotherapies for High-Risk Smoldering Myeloma
This study looks at new ways to treat Smoldering Multiple Myeloma, a condition that currently has no approved treatments. Researchers want to see if a newer immunotherapy, Teclistamab, can help stop this early-stage cancer from turning into active disease compared to standard treatments.
You may be eligible if you are at least 18 years old and have been diagnosed with high-risk Smoldering Multiple Myeloma. Eligibility depends on specific blood tests and the percentage of abnormal plasma cells found in your bone marrow.
Participants will be assigned to receive either the newer drug Teclistamab or a combination of standard medications called Lenalidomide and Dexamethasone. You will be closely monitored by a medical team to see how your body reacts to the treatment and to keep you safe.
This study is currently recruiting volunteers at medical centers in Denver, Colorado, Boston, Massachusetts, and Portland, Oregon.
- 1The study tests a new immunotherapy for a condition that has few treatment options.
- 2Participation involves comparing a new approach against standard medical therapies.
- 3Your health and safety are the top priority throughout the entire study process.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.